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Abstract Autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS: MIM 270550) is a neurodegenerative
disorder characterized by early-onset cerebellar ataxia with
spasticity and peripheral neuropathy. This disorder, consid-
ered to be rare, was first described in the late seventies among
French Canadians in the isolated Charlevoix-Saguenay region
ofQuebec.Nowadays,itisknownthatthedisorderisnot only
limitedtothisregionbutoccursworldwide.Ourobjectivewas
to identify cases of autosomal recessive spastic ataxia of
Charlevoix-Saguenay (ARSACS) in Dutch patients with
recessive early-onset cerebellar ataxia by sequencing the
complete SACS gene. In a Dutch cohort of 43 index patients
with ataxia onset before age 25, we identified 16 index
patients (total 23 patients) with mutations in the SACS gene.
Nine of them had homozygous mutations, and seven of them
had compound heterozygous mutations. Retrospectively, the
phenotype of patients carrying mutations was remarkably
uniform: cerebellar ataxia with onset before age 13 years,
lower limb spasticity and sensorimotor axonal neuropathy, and
cerebellar (vermis) atrophy on magnetic resonance imaging,
consistent with the core ARSACS phenotype previously
described. The high rate of mutations (37%) identified in this
cohort of Dutchpatients suggests that ARSACS is substantially
more frequent than previously estimated. We predict that the
availability of SACS mutation analysis as well as an increasing
awareness of the characteristic ARSACS phenotype will lead
to the diagnosis of many additional patients, possibly even at
a younger age.
Keywords Early onsetspasticcerebellarataxia.
Dutchpopulation.NovelSACSgenemutations.ARSACS
Introduction
Autosomal recessive spinocerebellar ataxias constitute a
heterogeneous group of neurodegenerative disorders char-
acterized by ataxia mostly due to progressive degeneration
of the cerebellum, spinal cord tracts, and associated
structures. The clinical phenotype of these disorders is
broad and quite variable. A number of recent reviews
presented clinical diagnostic strategies to differentiate
between the various types of recessive cerebellar ataxias
[1–3]. Van de Warrenburg et al. grouped them into
recognizable and more or less specific phenotypes: (a)
ataxia with neuro(no)pathy, (b) spastic ataxia, (c) ataxia
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Nijmegen, The Netherlandswith oculomotor apraxia, and (d) Ramsay Hunt syndrome.
The most common form, and representative of the first
group, is Friedreich’s ataxia (FRDA). Autosomal recessive
spastic ataxia of Charlevoix-Saguenay (MIM 270550),
ARSACS, is a distinct form of hereditary early-onset
spastic ataxia. The disease was first described in the
Charlevoix-Saguenay region of Northeastern Québec in
Canada [4]. Two founder mutations were identified in this
population [5]. Shortly after mutation analysis became
available, patients outside Québec were molecularly char-
acterized. To date, apart from the two Québec mutations, 27
different additional mutations have been found in ARSACS
patients outside Quebec, namely from Turkey, Tunisia,
Italy, Spain, Japan, and recently from Belgium [6–20]. The
SACS gene is located on chromosome 13q12.12 and
encodes the large protein sacsin [5]. Different transcripts
of the gene have been identified, and in total, 11 different
exons within the gene have been described. The large
transcript NM_014363.4 reported recently (www.ncbi.nlm.
nih.gov) comprises nine coding exons consisting of 13,737
base pairs which encode 4,579 amino acids [6]. The large
size of the total coding sequence of the SACS gene has
precluded sequencing efforts for routine diagnostic use.
The function of the sacsin protein is not yet known, but
the protein may be involved in chaperone-mediated
protein folding, as it contains a DnaJ domain and has
some sequence similarity with the N terminus of the heat
shock protein 90 (Hsp90) [5]. As ARSACS is now known
to occur worldwide, we initiated a systematic mutation
analysis by direct automated sequencing of the SACS
exons and flanking intronic sequences in Dutch patients
with an early-onset cerebellar ataxia presenting before the
age of 25, with the aim of identifying additional mutations
and determining the relative frequency of ARSACS
among the autosomal recessive cerebellar ataxias in the
Dutch population.
Materials and methods
Patient selection
To determine the frequency of ARSACS among patients
with early-onset cerebellar ataxia, we included in this study
patients who presented with an early-onset cerebellar ataxia
before the age of 25 and for whom Friedreich’s ataxia was
excluded through DNA mutation analysis. According to the
clinical information which was either given on the DNA
mutation analysis request form or gathered from medical
records, 43 index patients fulfilled this criterion. Patients
were recruited either through our own neurogenetics out-
patient clinic (n=26) as well as through referring neurolo-
gists and clinical geneticists from other hospitals (n=17).
Forty-one are native Dutch patients, one patient is of
English descent, and one is of Turkish descent.
Molecular analysis
Molecular analysis was performed in 43 index patients.
Genomic DNA was extracted from blood lymphocytes
using standard procedures. We performed sequence analysis
of the transcript of the SACS gene (NM_014363.4)
mentioned in the NCBI database (www.ncbi.nlm.nih.gov)
that comprises nine exons. The nine coding exons,
including the gigantic exon described previously [5], as
well as flanking intronic sequences of the SACS gene
[GenBank reference sequence accession number
NM_014363.4 (NCBI)] were polymerase chain reaction
(PCR)-amplified from genomic DNA by using 45 primer
pairs. The A of the ATG start codon in exon 1 is defined as
“position 1” for the numbering of nucleotides in mutation
and DNA-variant nomenclature. Primer sequences and
amplification parameters are available on request. Purified
PCR products (using Multiscreen PCRm96 filter plate,
Millipore Carrigtwohill, Cork, Ireland) were directly se-
quenced on an ABI 3730 automated sequencer (Applied
Biosystems, Foster City, CA, USA). In addition, mutation
analysis was performed in affected siblings or relatives of
patients with one homozygous or two compound heterozy-
gous mutations in the SACS gene. If available, parental
DNA was analyzed to confirm the location of the mutation
(s) in different SACS alleles. In all patients in whom no
mutations in the nine coding exons of the NM_014363.4
transcript of the SACS gene could be identified, we
performed molecular analysis of the additional two exons
within the other transcripts.
Clinical assessment
A systemic and comprehensive clinical examination by a
neurologist, a cardiologist, and an ophthalmologist was
performed in 16 identified patients, with mutations in the
SACS gene, of families 1 through 4, 6, 7, 8 through 11, and
13 (Tables 1 and 2) after having obtained informed written
consent. For our clinical assessments, we used the Scale for
the Assessment and Rating of Ataxia (SARA), an eight-
item scale that provides a comprehensive rating of simple
ataxia tests: (item 1) gait, (item 2) stance, (item 3) sitting,
(item 4) speech disturbance, (item 5) finger chase, (item 6)
nose-finger test, (item 7) fast alternating hand movements,
and (item 8) heel-shin slide [21]. We generated three
composite subscores by taking the average scores of the
subsets of SARA items. Averaging the scores of SARA
items 1, 2, and 8 generated a lower body ataxia composite
subscore that ranges from 0 (no ataxia) to 6 (most severe
ataxia). An upper body composite subscore consisted of
208 Neurogenetics (2008) 9:207–214items 5, 6, and 7. The maximum scores on composite
subscores may range from 0 (no ataxia) to 4 (severe ataxia).
A “remaining” ataxia composite subscore consisted of
items 3 and 4 that range from 0 (no ataxia) to 5 (worst).
Finally, to fully characterize patients and compare the three
composites, we normalized these subscores to percentages
of the maximum score. Lower body spasticity was
separately and semi-quantitatively rated according to the
INAS (Inventory of Non-Ataxia Symptoms) as, none, mild,
moderate, or severe [21]. Furthermore, the ataxia disease
stages were defined as: 0 = normal; 1 = ataxia, but walking
independently; 2 = permanently dependent on walking aids;
3 = permanently dependent on wheelchair; and 4 = death
[22]. If possible, clinical records of previous neurological
consultations were reviewed to obtain data on the disease
progression.
Results
Mutation analysis
In 16 out of 43 index patients, mutations in the SACS gene
were identified. In six families, the mutations could be
confirmed in seven additional affected siblings or relatives.
We thus identified mutations in 23 patients. Molecular
genetic analysis revealed nine index patients with homozy-
gous mutations and seven index patients with compound
heterozygous mutations (Table 1). In total, 16 different
novel mutations were identified: eight nonsense, three
missense, two splice-site, one in frame deletion, and two
frame-shift mutations (Table 1). The mutations occurred
throughout the whole gene without any hot-spot regions
(Fig. 1). All mutations most likely lead to a loss of function.
For the in frame deletion (p.2801delGln) in family 9, the
prediction programs are inconclusive. Whether this muta-
tion indeed leads to a loss of function is unknown.
However, the p.2801delGln mutation segregated with the
disease in the family was not identified in 100 control
alleles, and the mutation is located in a conserved region of
the gene. In general, a 3-bp deletion is considered to have a
larger deleterious effect on the protein function than a
missense mutation. All three patients carrying the
p.2801delGln display a relatively severe phenotype, as all
were wheelchair-bound before the age of 15. In family 3,
the identified heterozygous missense mutation (p.
Arg4331Gln) is located in the highly conserved DnaJ
domain in exon 6 of the SACS gene. This mutation is
predicted to be intolerant (PolyPhen—www.genetics.bwh.
harvard.edu/pph/—and SIFT—www.blocks.fhcrc.org/sift/
SIFT.html) and probably leads to loss of function of the
protein. The mutation (c. 2094-2 A>G) in family 6
presumably induces skipping of exon 5 due to loss of the
splice-acceptor site (www.fruitfly.org/cgi-bin/seq_tools/
splice.htlml, www.cbs.dtu.dk/services/NetGene2/, www.
genet.sickkids.on.ca/~ali/splicesitefinder.html). Skipping of
exon 5 most likely leads to absence of sacsin protein. The
transcript lacking exon 5 is likely subject to nonsense-
mediated messenger RNA decay (NMD) due to a
downstream protein truncating codon (PTC) occurring as
a result of a shift of the reading frame. The splice site
mutation (c.1891+1 del G) in family 11 affects the splice-
donor site, either leading to a downstream PTC and
subsequent NMD or to skipping of exon 5. The identified
homozygous missense mutation (p.Asp168Tyr) in family 7
is considered to be pathogenic because the amino acid
chance is predicted to be intolerant (PolyPhen and SIFT),
the change is located in a conserved region, and was not
identified in 100 control alleles. The same mutation was
also identified in another affected relative of whom both
Table 1 Homozygous or
compound heterozygous muta-
tions in SACS gene
aNon-Dutch patients
Family Consanguinity Mutations Type of mutation
1 Yes p.Gln4054X/p.Gln4054X Nonsense
2 Yes p.Arg728X/p.Arg728X Nonsense
3 No p.Lys1715X/p.Arg4331Gln Nonsense/Missense
4 No p.Gln4054X/p.Arg2002fs Nonsense/Frameshift
5
a Yes p.Glu1653X/p.Glu1653X Nonsense
6 No p.Gln4054X/c.2094-2 A>G Nonsense/Splice-site
7 Yes p.Asp168Tyr/p.Asp168Tyr Missense
8 No p.Gln4054X/p.Gln4054X Nonsense
9 Yes p.2801delGln/p.2801delGln In frame deletion
10 Not known p.Gln4054X/p.Gln4054X Nonsense
11 No c.1891+1 del G/c.1891+1 del G Splice-site
12 Not known p.Gln1709X/p.Gln4054X Nonsense
13 No p. Arg321X/p. Arg3636X Nonsense
14 No p.Gln4054X/p.Gln4054X Nonsense
15 No p.Arg321X/p.Trp492X Nonsense/Nonsense
16
a No p.Leu3304fs/p.Leu3481Pro Frameshift/Missense
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210 Neurogenetics (2008) 9:207–214parents were also consanguineous within the same extended
family. The mutation most likely leads to a conformation
change of the protein resulting in dysfunction of the
protein. The missense mutation identified in family 16
(English descent) is most likely pathogenic because it
concerns a drastic change of an evolutionary highly
conserved amino acid; however, we are still waiting for
DNA to confirm the mutation in the affected sibling. The
nonsense mutation p.Gln3907X, identified in 7 out of 14
unrelated Dutch ARSACS patients is a common Dutch
nonsense mutation.
Clinical data
Twenty-one patients from 14 different families with
homozygous or compound heterozygous mutations in the
SACS gene were of Dutch descent. Family 5 originated
from Turkey and family 16 is from English descent. All
patients identified were adults, but onset of gait impairment
in the 21 patients of whom clinical data were available was
before age 13 (mean 3.7 years, SD 3.1, range 1–12). The
mean disease duration in these 21 patients was 36.2 years
(SD 9.9, range 25–56). Clinically, all identified patients
carrying SACS mutations showed a remarkable uniform
phenotype: mild to moderate ataxia of the upper half of the
body with a severe spastic paresis, with sensory and motor
neuropathy of the lower limbs and very mild motor
neuropathy of the upper limbs, and with cerebellar atrophy
on neuroimaging (Table 2). This phenotype is consistent
with the core ARSACS phenotype previously described.
Atthetimeoftheclinicalexamination,themajority(n=13)
of the patients were permanently wheelchair-dependent. The
current clinical details in combination with older medical
records suggest that the initial years of disease were
dominated by a slowly progressive cerebellar ataxia with
subsequent lower limb spasticity, followed by features of
peripheral neuropathy. This ultimately led to an impressive
and severe lower limb and gait impairment, while oculomo-
tor disturbances, dysarthria, and upper limb ataxia appeared
to progress much slower. The sensorimotor peripheral
neuropathy was evident from distal muscle atrophy and
weakness, foot deformities, impaired tactile and vibration
sense, and eventually a decrease or loss of tendon reflexes in
the legs. Slight dysphagia and urinary dysfunction (predom-
inantly urge incontinence) were fairly common. Three
patients (no. 9, no. 11, and no. 12) displayed subtle yet
unequivocal abnormal posturing of the hands and/or neck,
indicative of mild dystonia in these patients; other extrapy-
ramidal features were absent. Two patients (no. 4 and no. 20)
used an intrathecal Baclofen pump, which influences the
outcome of the SARA score on lower limb function. In our
Dutch ARSACS cohort, no patient was mentally retarded nor
showed signs of dementia. Only two patients displayed mild
cognitive problems. One of these (no. 15), had suffered from
meningitis at age 44 and developed diabetes at age 56. He
had experienced a recent episode of epileptic seizures. The
other patient (no. 20) had suffered from strokes. In 15
patients who had undergone a brain magnetic resonance
imaging (MRI) or computed tomography (CT) scan, moder-
ate to severe mid-cerebellar (vermis) atrophy was noticed,
the severity of which appeared to parallel disease duration. In
12 patients, an electrocardiogram (ECG) was made and
echocardiography was performed. One patient (no. 1)
showed a right bundle branch block on ECG; no other
ECG abnormalities were seen either in this patient or in any
other. None of the examined patients displayed signs of
mitral valve prolapse or any other cardiac abnormalities on
echocardiography. On ophthalmologic examination, all 14
patients that were examined showed demarcation of the
retinal nerve fibers that embedded parts of the vessels near
the disc (Fig. 2). In one patient (no. 7), a papilla leparina
could be seen. In patients no. 19 and no. 20, no
ophthalmologic examination and cardiologic examination
was done, and no cardiologic examination could be
performed in patient no. 6 due to limited mobility.
Discussion
In this report, we demonstrate that in the Dutch population,
mutations in the SACS gene are quite prevalent among
patients with early-onset cerebellar ataxia. Moreover, those
DnaJ
HEPN
reverse strand
NM_014363.4
M N N Ss Ss N N N N F F ∆ NM Na M Fig. 1 Overview of different
mutations in the SACS gene. M
missense, N
a founder, N non-
sense, Δ deletion, F frameshift,
Ss splice site
Neurogenetics (2008) 9:207–214 211who harbored mutations in the SACS gene showed a strikingly
uniform and recognizable clinical phenotype consisting of
cerebellar ataxia with onset before the age of 13, lower limb
spasticity and sensorimotor axonal neuropathy, and cerebellar
(vermis) atrophy on neuroimaging.
Originally believed to be a rare disease that was present
in Quebec only, ARSACS turns out to constitute a fairly
common phenotype in the diverse group of early-onset
recessive cerebellar ataxias. We identified many different
novel mutations throughout the whole gene. The clinical
phenotype is specific and recognizable, thus offering a
good indication for mutation analysis. In this study, the
detection rate of ARSACS mutations in the SACS gene
among 43 patients with an early-onset recessive cerebellar
ataxia was 37%. Retrospectively, we can conclude that all
identified ARSACS patients displayed mild to moderate
upper body ataxia and severe spastic paresis of the lower
limbs with neuropathy. In two patients with more or less
similar neurological features, no mutations in the SACS
gene could be identified. This might be due to genetic
heterogeneity for the spastic ataxia phenotype. The
principle of genetic heterogeneity for the spastic ataxia
phenotype is demonstrated by reports of patients with
spastic ataxia who harbor mutations in the FRDA gene
and of patients who are linked to the SPG30, SAX2, and
ARSAL loci [23–28].
Furthermore, in retrospect, these two patients had less
lower limb spasticity compared to the ARSACS patients
and, contrary to these, prominent atrophy and weakness of
the intrinsic hand muscles. On the other hand, we cannot
exclude that mutations in both SACS alleles might have
remained undetected, for instance when they reside in parts
of the gene that have not been analyzed, e.g., regulatory
regions upstream of the gene or deep in the introns. The
average age of onset of the disease in our cohort is
comparable to what has been described in literature, except
for one Tunisian case in whom the age of onset was
20 years [29].
Mitral valve prolapse has been mentioned as a frequent
feature among ARSACS patients from Quebec [4]. After
the publication of Bouchard et al. [4], cardiac involvement
in ARSACS patients has not been further reported. This is
consistent with the absence of cardiac symptoms in patients
from our cohort. Therefore, we conclude that cardiac
involvement is not a clinical characteristic of ARSACS.
Increased demarcation of the retinal fibers embedding parts
of the vessels near the disc has previously been reported as
being a common feature of ARSACS among patients
originating from Quebec and of some other ARSACS
patients [4, 8, 9, 13, 15, 30, 31]. Eight of the 14 patients
whom we ophthalmologically examined not only did show
increased demarcation of the retinal nerve fibers but also
had a distinct tortuosity of the retinal vessels near the optic
disc (Fig. 2).
Our data demonstrate that mental retardation, defined as
having an IQ of less than 70, is not a feature of ARSACS.
S of a r ,o n l yt w oA R S A C Sp a t i e n t sd e s c r i b e di nt h e
literature fulfill this criterion. However, as their spastic-
ataxic sibs were not mentally retarded, the retardation is
most likely an independent feature not related to ARSACS
[13, 17]. In three patients, mild dystonic features were
observed. Dystonia has not been reported in other ARSACS
patients, but extrapyrimadal features such as dystonia and
chorea are known to occur in Friedreich’s ataxia, ataxia
telangiectasia, ataxia with oculomotor apraxia type 1, and
ataxia with vitamin E [32–35]. So far, only two adult
ARSACS patients (with mutations in the SACS gene)
without lower limb spasticity have been reported. The
absence of this feature was suggested to be due to the
severe progressive neuropathy that could mask spasticity
[9, 18]. Assuming a uniform clinical ARSACS phenotype
and given the still labor-intensive procedure of fully
sequencing this large gene, it seems currently advisable to
screen the SACS gene only in those patients who present
with early-onset slowly progressive cerebellar ataxia, with
lower limb spasticity and peripheral neuropathy, with
relatively mild oculomotor disturbances and upper limb
ataxia, and in whom Friedreich’s ataxia has been excluded.
In conclusion, 16 novel SACS mutations were identified
in 16 different families consisting of 23 patients in whom
the clinical phenotype was very similar and consistent with
the core ARSACS phenotype, mild to moderate upper body
ataxia and severe spastic paresis of the lower limbs and
neuropathy, with cerebellar atrophy revealed by neuro-
imaging. The identification of several different mutations in
the SACS gene in this first mutational screen in Dutch
patients with an early-onset cerebellar ataxia indicates that
Fig. 2 Red-free fundus photograph of patient no. 12; increased
demarcation of the retinal nerve fibers, partially embedded retinal
vessels; and a distinct tortuosity of the retinal vessels near the optic
disc are seen
212 Neurogenetics (2008) 9:207–214ARSACS is more prevalent in the Dutch population than
previously assumed. This could also be the case in other
populations.
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